5 results about "Clonidine" patented technology

The application discloses a sustained-release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations. The patch is a five-layer composite structure, and the key lies in that: the adhesive layer and the drug depot layer both contain ion pairs of clonidine and organic acid formed in situ under specific solvent and temperature conditions, and the formation of the ion pairs is confirmed by pH value or infrared spectrum; and specific transdermal penetration enhancers are further compounded, so that programmed controlled release is realized through the cooperation of the two layers. The preparation process adopts the sequence of forming ion pairs first and then mixing, realizes coating precision of ±2μm through slit extrusion coating combined with online thickness measurement closed-loop control, adopts gradient drying process with clear temperature zone, air speed and humidity parameters, and carries out real-time quality control based on the online near-infrared spectrum detection of the pre-established PLS regression model. The process can ensure that the patch realizes near-zero-order constant-speed release within 168h, and has the advantages of stable drug release, uniform content, stable quality and high batch consistency.

The invention discloses a sustained and controlled release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations, the patch is of a five-layer composite structure, and the patch is characterized in that an adhesive layer and a drug storage layer both contain ion pairs formed by clonidine and organic acid in situ under specific solvent and temperature conditions; the formation of the composition is confirmed through a pH value or an infrared spectrum, then a specific percutaneous penetration enhancer is compounded, and programmed controlled release is realized through double-layer synergy. The preparation process adopts a sequence of firstly forming ion pairs and then mixing, the coating precision of + / -2 microns is realized by matching slit extrusion coating with on-line thickness measurement closed-loop control, and real-time quality control is performed by adopting a gradient drying process with clear temperature zone, wind speed and humidity parameters and on-line near infrared spectrum detection based on a pre-established PLS regression model. The process disclosed by the invention can ensure that the patch realizes near-zero-level constant-speed release within 168 hours, and has the advantages of stable drug release, uniform content, stable quality and high inter-batch consistency.

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg / mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

The present disclosure relates generally to a ready-to-use oral liquid formulation of clonidine or pharmaceutically acceptable salt thereof, as well as methods of manufacture and use.

The application prepares a hyaluronic acid-encapsulated dexmedetomidine microneedle system, which is verified by multidimensional characterization, and the microneedle system has excellent forming property, mechanical property, transdermal and drug release performance, has the characteristics of rapid effect (0.5h cumulative release 43.3%) and long-term delivery (4h cumulative release 86.5%), and has good biocompatibility, and the behavior and electrophysiology experiments confirm that the anti-haze and anti-vomiting effect is remarkable, and because the alpha 2 receptor selectivity is higher, the effect is better than that of clonidine.